1,977 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Cassaday & Co Wealth Management LLC

Cassaday & Co Wealth Management LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,977 shares of the company’s stock, valued at approximately $235,000.

Other hedge funds have also made changes to their positions in the company. 1620 Investment Advisors Inc. purchased a new stake in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth $25,000. Halpern Financial Inc. boosted its position in Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Finally, Abound Wealth Management grew its stake in Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after purchasing an additional 157 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $99.82 on Tuesday. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The firm has a fifty day simple moving average of $117.94 and a 200-day simple moving average of $129.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $447.95 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 1.31 and a beta of 0.42.

Analysts Set New Price Targets

NVO has been the subject of a number of recent research reports. BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.